title: [Treatment outcome of myelodysplastic syndrome patients younger than 60 years old].
abstract: We evaluated the clinical outcome of 92 patients younger than 60 years who were treated between January 1987 and May 2003. Low, Int-1, Int-2 and High risk groups categorized by IPSS consisted of 7, 34, 24 and 27 patients, respectively. There was no significant difference in the overall survival between 30 patients who received allogeneic stem cell transplantation and 62 patients who did not. Allogeneic stem cell transplantation provided significantly better outcomes in the Int-2 and the High risk groups. Risk factors for overall survival were age and disease status at transplantation. Acute and chronic GVHD did not influence the relapse free survival rate. Allogeneic stem cell transplantation is a curative therapy for MDS. It is necessary to reduce transplantation related death and to perform stem cell transplantation as soon as possible for patients with Int-2 or High risk of IPSS.
authors.affiliation: Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Matsushima
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Handa
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yokohama
authors.forename: Tohru
authors.initials: T
authors.lastname: Sakura
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Okamoto
authors.forename: Toshihide
authors.initials: T
authors.lastname: Kawamura
authors.forename: Yuki
authors.initials: Y
authors.lastname: Tsumita
authors.forename: Kayoko
authors.initials: K
authors.lastname: Murayama
authors.forename: Atsushi
authors.initials: A
authors.lastname: Isoda
authors.forename: Takahiro
authors.initials: T
authors.lastname: Jinbo
authors.forename: Hisami
authors.initials: H
authors.lastname: Hirabyashi
authors.forename: Morio
authors.initials: M
authors.lastname: Sawamura
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Karasawa
authors.forename: Shun-ichi
authors.initials: S
authors.lastname: Shimano
authors.forename: Norifumi
authors.initials: N
authors.lastname: Tsukamoto
authors.forename: Shuichi
authors.initials: S
authors.lastname: Miyawaki
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nojima
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Murakami
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning; D016896:Treatment Outcome